Daubers, glad you're here. Newer PR: essentially, proof that Kevetrin DOES change things in the tumor (for the better, natch), and the strategy has now changed to making an oral formulation so that patients don't have to come in for IV therapy. This is both more convenient and means that they can dose themselves much more frequently -- not to mention painlessly.

http://www.ipharminc.com/press-release/2018/2...3-observed

Quote:

---

From the Press Release:
Throughout pre-clinical testing and two successful clinical trials, Kevetrin has demonstrated promising signs of efficacy as an anti-cancer agent and a favorable pharmacokinetic profile that includes a very short half-life and good bioavailability. It is believed that these characteristics make Kevetrin an ideal candidate for oral delivery (capsule or tablet), which will facilitate convenient and frequent dosing, perhaps even multiple times daily, to maximize the therapeutic benefit of the compound. With the positive observation of intra-tumor p53 modulation, the Company will now allocate resources to focus its efforts on completing development of an oral formulation, including performing bridging toxicology work.

---